Movement Alert｜Gilead Sciences Rises 3.2% Overnight, HSBC Upgrades to Buy with Target Price Raised to $155

Market Focus07-13

On July 13, Gilead Sciences rose 3.2% overnight, trading at $133.99/share with turnover of $434,200, rebounding notably from a period of consecutive pullbacks.

On the news front, HSBC recently upgraded Gilead Sciences from Hold to Buy and raised its target price significantly from $133 to $155, providing strong support for the stock. According to FactSet-polled analysts, the stock carries an average Buy rating with a mean price target of $160.74. Additionally, Gilead's core oncology product Trodelvy received FDA approval in late June for first-line treatment of advanced triple-negative breast cancer, available as monotherapy or in combination with Merck's Keytruda. The NCCN has designated it as a category 1 preferred treatment option regardless of PD-L1 status, opening new growth potential for the company's oncology segment.

The stock had previously declined 3.04% on July 10 amid broad weakness across the biotech sector. The current rebound appears to reflect the market re-pricing fundamental catalysts including the analyst upgrade and the expanded Trodelvy indication.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196586461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196586461","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Rises 3.2% Overnight, HSBC Upgrades to Buy with Target Price Raised to $155","media":"Market Focus","content":"<p><p>On July 13, Gilead Sciences rose 3.2% overnight, trading at $133.99/share with turnover of $434,200, rebounding notably from a period of consecutive pullbacks.</p><p>On the news front, HSBC recently upgraded Gilead Sciences from Hold to Buy and raised its target price significantly from $133 to $155, providing strong support for the stock. According to FactSet-polled analysts, the stock carries an average Buy rating with a mean price target of $160.74. Additionally, Gilead's core oncology product Trodelvy received FDA approval in late June for first-line treatment of advanced triple-negative breast cancer, available as monotherapy or in combination with Merck's Keytruda. The NCCN has designated it as a category 1 preferred treatment option regardless of PD-L1 status, opening new growth potential for the company's oncology segment.</p><p>The stock had previously declined 3.04% on July 10 amid broad weakness across the biotech sector. The current rebound appears to reflect the market re-pricing fundamental catalysts including the analyst upgrade and the expanded Trodelvy indication.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Rises 3.2% Overnight, HSBC Upgrades to Buy with Target Price Raised to $155</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Rises 3.2% Overnight, HSBC Upgrades to Buy with Target Price Raised to $155\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-13 12:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 13, Gilead Sciences rose 3.2% overnight, trading at $133.99/share with turnover of $434,200, rebounding notably from a period of consecutive pullbacks.</p><p>On the news front, HSBC recently upgraded Gilead Sciences from Hold to Buy and raised its target price significantly from $133 to $155, providing strong support for the stock. According to FactSet-polled analysts, the stock carries an average Buy rating with a mean price target of $160.74. Additionally, Gilead's core oncology product Trodelvy received FDA approval in late June for first-line treatment of advanced triple-negative breast cancer, available as monotherapy or in combination with Merck's Keytruda. The NCCN has designated it as a category 1 preferred treatment option regardless of PD-L1 status, opening new growth potential for the company's oncology segment.</p><p>The stock had previously declined 3.04% on July 10 amid broad weakness across the biotech sector. The current rebound appears to reflect the market re-pricing fundamental catalysts including the analyst upgrade and the expanded Trodelvy indication.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1196586461","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196586461","pubTimestamp":1783915342,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 13, Gilead Sciences rose 3.2% overnight, trading at $133.99/share with turnover of $434,200, rebounding notably from a period of consecutive pullbacks.On the news front, HSBC recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势警报|吉利德科学隔夜上涨3.2%，汇丰银行上调买入评级，目标价上调至155美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On July 13, Gilead Sciences rose 3.2% overnight, trading at $133.99/share with turnover of $434,200, rebounding notably from a period of consecutive pullbacks.On the news front, HSBC recently upgraded Gilead Sciences from Hold to Buy and raised its target price significantly from $133 to $155, providing strong support for the stock. According to FactSet-polled analysts, the stock carries an average Buy rating with a mean price target of $160.74. Additionally, Gilead's core oncology product Trodelvy received FDA approval in late June for first-line treatment of advanced triple-negative breast cancer, available as monotherapy or in combination with Merck's Keytruda. The NCCN has designated it as a category 1 preferred treatment option regardless of PD-L1 status, opening new growth potential for the company's oncology segment.The stock had previously declined 3.04% on July 10 amid broad weakness across the biotech sector. The current rebound appears to reflect the market re-pricing fundamental catalysts including the analyst upgrade and the expanded Trodelvy indication.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196586461","isCrawlerRequest":true}